China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval
Retrieved on:
Friday, March 17, 2023
Survival rate, IIT, Center for Drug Evaluation and Research, DC, Clinical trial, Cancer, Chinese, B cell, Messenger, Patient, National Medical Products Administration, Immune system, 301 Hospital, CDE, Hospital, Recurrence, IND, NMPA, Tumor-associated calcium signal transducer, Safety, Pharmaceutical industry, Vaccine
This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.
Key Points:
- This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.
- LK101 Injection, the first in-house developed cancer vaccine candidates by Likang, is a personalized neoantigen-targeted cancer vaccine and also a dendritic cell (DC)-based mRNA vaccine that combines advantages of both mRNA technology and DC by transducing mRNA encoding personalized tumor antigen targets based on dozens of patient-specific tumor mutations information into dendritic cells.
- The combination of mRNA vaccine and DC vaccine provides a potential breakthrough in the field of personalized neoantigen treatment, offering an effective and safe approach for patients to fight against cancer.
- In 2018, Likang collaborated with the Chinese PLA General Hospital to conduct an investigator-initiated clinical trial (IIT) of LK101 injection for postoperative liver cancer patients.